Answers are grounded in this paper and cite their sources.
Bedaquiline and delamanid are effective and might be safe in patients with chronic kidney or liver disease. MDR-TB patients with these comorbidities receiving bedaquiline and/or delamanid have poor treatment outcomes, probably owing to the comorbidities. https://bit.ly/3NyDD15
No takes yet. Share an insight, caveat, or question.
Chung et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: